Subject:
- Active Substance: Trastuzumab deruxtecan
- Name: Enhertu®
- Therapeutic area: Breast cancer
- Pharmaceutical company: Daiichi Sankyo Deutschland GmbH
Time table:
- Start: 01.02.2023
- Final decision by G-BA: 20.07.2023
Final decision:
- Indication for a considerable additional benefit